A significantly higher likelihood of receiving ICIs was observed among female patients (vs males), patients initially diagnosed at stage I-III (vs stage IV), with colon cancer (vs rectal cancer), MSI-H tumors (vs MSS tumors), BRAF mutations (vs wild-type), or diagnosed after FDA approval (vs before). Here, BRAF is linked to rectal cancer.